Canadian Journal of Cardiology

Routine Prophylactic Cardioprotective Therapy Should Be Given to All Recipients at Risk of Cardiotoxicity From Cancer Chemotherapy

  • Author Footnotes
    ∗ Husam Abdel-Qadir and Mark T. Nolan are co-first authors.
    Husam Abdel-Qadir
    ∗ Husam Abdel-Qadir and Mark T. Nolan are co-first authors.
    Division of Cardiology, Women's College Hospital, Toronto, Ontario, Canada
    Search for articles by this author
  • Author Footnotes
    ∗ Husam Abdel-Qadir and Mark T. Nolan are co-first authors.
    Mark T. Nolan
    ∗ Husam Abdel-Qadir and Mark T. Nolan are co-first authors.
    Menzies Institute for Medical Research, Hobart, Australia
    Search for articles by this author
  • Paaladinesh Thavendiranathan
    Corresponding author: Dr Paaladinesh Thavendiranathan, Peter Munk Cardiac Center, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, University of Toronto, 4N-490, 585 University Ave, Toronto, Ontario M5G 2N2, Canada. Tel.: +1-416-340-5326; fax: +1-416-340-3640.
    Division of Cardiology, Peter Munk Cardiac Centre and the Joint Division of Medical Imaging, Ted Rogers Program in Cardiotoxicity Prevention, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Search for articles by this author
  • Author Footnotes
    ∗ Husam Abdel-Qadir and Mark T. Nolan are co-first authors.
Published:April 26, 2016DOI:


      The inevitability of cardiac injury in many patients treated for cancer mandates strategies to mitigate the effect of cancer treatment on the heart. In this article we argue that the best approach to prevent cardiotoxicity is universal primary prevention for everyone at risk for irreversible myocardial injury. Our viewpoint is on the basis of 5 major arguments that we discuss in detail in this article. We outline the shortcomings of alternate strategies for prevention and highlight that the strongest existing evidence today supports our viewpoint. In particular, data from multiple randomized controlled trials indicate that most patients who receive anthracyclines are at risk, and should be accordingly considered for primary prevention.


      Comme les lésions cardiaques sont inévitables chez bon nombre de patients recevant un traitement anticancéreux, il est nécessaire de mettre en place des stratégies pour atténuer les effets de ce type de traitement sur le cœur. Dans cet article, nous soutenons que le meilleur moyen de prévenir la cardiotoxicité est la prévention primaire systématique chez les patients à risque de lésion myocardique irréversible. Notre position est étayée par 5 arguments importants présentés en détail dans cet article. Nous soulignons les faiblesses des autres stratégies et le fait que les données existantes les plus probantes corroborent notre point de vue. Il est particulièrement à noter que les données provenant de multiples études contrôlées à répartition aléatoire indiquent que la plupart des patients qui reçoivent des anthracyclines sont exposés à un risque et, par conséquent, il faudrait, dans ces cas, envisager la prévention primaire.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jones L.W.
        • Haykowsky M.J.
        • Swartz J.J.
        • Douglas P.S.
        • Mackey J.R.
        Early breast cancer therapy and cardiovascular injury.
        J Am Coll Cardiol. 2007; 50: 1435-1441
        • Lotrionte M.
        • Biondi-Zoccai G.
        • Abbate A.
        • et al.
        Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity.
        Am J Cardiol. 2013; 112: 1980-1984
        • Swain S.M.
        • Whaley F.S.
        • Ewer M.S.
        Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
        Cancer. 2003; 97: 2869-2879
        • Chen J.
        • Long J.B.
        • Hurria A.
        • et al.
        Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
        J Am Coll Cardiol. 2012; 60: 2504-2512
        • Levine G.N.
        • D’Amico A.V.
        • Berger P.
        • et al.
        Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.
        Circulation. 2010; 121: 833-840
        • Thavendiranathan P.
        • Abdel-Qadir H.
        • Fischer H.
        • et al.
        Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: a population-based cohort study [Epub ahead of print].
        J Clin Oncol. 2016; (Apr 18. pii: JCO651505.)
        • Amir E.
        • Seruga B.
        • Niraula S.
        • Carlsson L.
        • Ocana A.
        Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
        J Natl Cancer Inst. 2011; 103: 1299-1309
        • Hull M.C.
        • Morris C.G.
        • Pepine C.J.
        • Mendenhall N.P.
        Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy.
        JAMA. 2003; 290: 2831-2837
        • Plana J.C.
        • Galderisi M.
        • Barac A.
        • et al.
        Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
        J Am Soc Echocardiogr. 2014; 27: 911-939
        • Kalam K.
        • Marwick T.H.
        Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
        Eur J Cancer. 2013; 49: 2900-2909
        • Acar Z.
        • Kale A.
        • Turgut M.
        • et al.
        Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.
        J Am Coll Cardiol. 2011; 58: 988-989
        • Cardinale D.
        • Colombo A.
        • Sandri M.T.
        • et al.
        Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
        Circulation. 2006; 114: 2474-2481
      1. Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol [Epub ahead of print]. Eur Heart J, Accessed February 21, 2016.

        • van Dalen E.C.
        • Caron H.N.
        • Dickinson H.O.
        • Kremer L.C.
        Cardioprotective interventions for cancer patients receiving anthracyclines.
        Cochrane Database Syst Rev. 2011; : CD003917
        • Edwards B.K.
        • Noone A.M.
        • Mariotto A.B.
        • et al.
        Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.
        Cancer. 2014; 120: 1290-1314
        • Cardinale D.
        • Sandri M.T.
        • Martinoni A.
        • et al.
        Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.
        J Am Coll Cardiol. 2000; 36: 517-522
        • Thavendiranathan P.
        • Poulin F.
        • Lim K.D.
        • et al.
        Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.
        J Am Coll Cardiol. 2014; 63: 2751-2768
        • Zhang S.
        • Liu X.
        • Bawa-Khalfe T.
        • et al.
        Identification of the molecular basis of doxorubicin-induced cardiotoxicity.
        Nat Med. 2012; 18: 1639-1642
        • Torti F.M.
        • Bristow M.M.
        • Lum B.L.
        • et al.
        Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.
        Cancer Res. 1986; 46: 3722-3727
        • Cardinale D.
        • Sandri M.T.
        • Colombo A.
        • et al.
        Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.
        Circulation. 2004; 109: 2749-2754
        • Sawaya H.
        • Sebag I.A.
        • Plana J.C.
        • et al.
        Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
        Circ Cardiovasc Imaging. 2012; 5: 596-603
        • Romond E.H.
        • Jeong J.H.
        • Rastogi P.
        • et al.
        Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
        J Clin Oncol. 2012; 30: 3792-3799
        • Ezaz G.
        • Long J.B.
        • Gross C.P.
        • Chen J.
        Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
        JAMA. 2014; 3: e000472
        • Cardinale D.
        • Colombo A.
        • Bacchiani G.
        • et al.
        Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
        Circulation. 2015; 131: 1981-1988
        • Cardinale D.
        • Colombo A.
        • Lamantia G.
        • et al.
        Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
        J Am Coll Cardiol. 2010; 55: 213-220
        • Chavez-MacGregor M.
        • Niu J.
        • Zhang N.
        • et al.
        Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer.
        J Clin Oncol. 2015; 33: 2176-2183
        • Thavendiranathan P.
        • Grant A.D.
        • Negishi T.
        • et al.
        Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
        J Am Coll Cardiol. 2013; 61: 77-84
        • Kalam K.
        • Otahal P.
        • Marwick T.H.
        Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction.
        Heart. 2014; 100: 1673-1680
        • Nolan M.T.
        • Plana J.C.
        • Thavendiranathan P.
        • et al.
        Cost-effectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity.
        Int J Cardiol. 2016; 212: 336-345
        • Bosch X.
        • Rovira M.
        • Sitges M.
        • et al.
        Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
        J Am Coll Cardiol. 2013; 61: 2355-2362
        • Mann D.L.
        • Bristow M.R.
        Mechanisms and models in heart failure: the biomechanical model and beyond.
        Circulation. 2005; 111: 2837-2849
        • Howlett J.G.
        • Chan M.
        • Ezekowitz J.A.
        • et al.
        The Canadian Cardiovascular Society Heart Failure Companion: bridging guidelines to your practice.
        Can J Cardiol. 2016; 32: 296-310
        • Taylor F.
        • Huffman M.D.
        • Macedo A.F.
        • et al.
        Statins for the primary prevention of cardiovascular disease.
        Cochrane Database Syst Rev. 2013; 1: CD004816
        • Echouffo-Tcheugui J.B.
        • Ergou S.
        • Butler J.
        • et al.
        Assessing the risks of progression from asymptomatic left ventricualr dysfunction to overt heart failure: a sytematic overview and meta-analysis.
        JACC Heart Fail. 2016; 4: 237-248
        • Wang T.J.
        • Evans J.C.
        • Benjamin E.J.
        • et al.
        Natural history of asymptomatic left ventricular systolic dysfunction in the community.
        Circulation. 2003; 108: 977-982
        • Jha P.
        • Ramasundarahettige C.
        • Landsman V.
        • et al.
        21st-century hazards of smoking and benefits of cessation in the United States.
        N Engl J Med. 2013; 368: 341-350
        • Preiss D.
        • Campbell R.T.
        • Murray H.M.
        • et al.
        The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.
        Eur Heart J. 2015; 36: 1536-1546
        • Daskalopoulou S.S.
        • Rabi D.M.
        • Zarnke K.B.
        • et al.
        The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.
        Can J Cardiol. 2015; 31: 549-568
        • Jong P.
        • Yusuf S.
        • Rousseau M.F.
        • Ahn S.A.
        • Bangdiwala S.I.
        Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
        Lancet. 2003; 361: 1843-1848